Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics

Truist initiated coverage on Edgewise Therapeutics Inc EWTX with a Buy rating and a price target of $25.

The analyst notes encouraging data from lead drug EDG-5506 in Becker Muscular Dystrophy (BMD), suggesting a benefit to muscle injury sustained over six months.

The company is advancing the CANYON trial evaluating EDG-5506 in individuals with BMD. CANYON will assess the effect of EDG-5506 over 12 months on safety, pharmacokinetics (PK), biomarkers, and functional measures

Edgewise Therapeutics expects to amend the CANYON study to include a potentially registration-enabling cohort in 2H of 2023.

The company is evaluating EDG-5506 in Duchenne muscular dystrophy (DMD). LYNX Phase 2 trial is ongoing, with interim data expected in Q4 of 2023.

The analyst writes that EDG-5506 has the potential to become standard-of-care in BMD and enhance efficacy as a combo partner with different modalities in DMD. 

While preclinical & early clinical data have been encouraging, long-term data from Ph1b & Ph2 data are likely needed to boost investor confidence, writes the analyst.

With data readouts expected over the next 12-18 months, Truist sees a favorable risk-reward profile for the stock, with a potential upside of 50%-200%.

Price Action: EWTX shares are up 11.20% at $9.75 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!